Episode Details
Back to Episodes
EHA 2025: Arcellx CEO Rami Elghandour discusses the results presented today of the iMMagine-1 Study for the company's BCMA CAR-T
Published 1 year, 3 months ago
Description
He goes over the results, and compares and contrasts the therapy's profile to the primary competitor that is currently on the market, Carvykti. Plus learnings from year two of a physician survey, and his current take on CAR-T for autoimmune and CD123 for AML.